“It is clear from this experiment that Theiler’s is not MS. Fingolimod works the same in mice as it does in man so the results cannot be explained away on a different mechanism of action of the drug between man and mice. Interesting? Yes, our disease models are just that models and should be interpreted in that way.”
A large number scientists in field rate Theiler’s virus infection in a particular strain of mice as a disease that is very close to MS.
Animals with this infection develop a progressive demyelinating condition.
Fingolimod is effective in MS and was therefore tried in this animal model of MS.
No significant differences were found in disability progression, viral load, and serum antibody responses between the Fingolimod-treated and placebo-treated mice.
Epub ahead of print: Li et al. The effect of FTY720 in the Theiler’s virus model of multiple sclerosis. J Neurol Sci. 2011 Jul 2.
See previous posts:
03 Jun 2011
What exactly are you planning on doing to change that Prof G? Having seen the Fingolimod corporate advert extolling its excellence I have to ask that if it is so effective why it is only approved for RRMS patients? …
30 Apr 2011
In addition to its immune effects Fingolimod readily penetrates the CNS and may have direct effects on neural cells. This central mechanism of action distinguishes Fingolimod from other immunosuppressive drugs and may …
02 May 2011
Fingolimod: brain volume data. As a follow-up to my comment on a previous posting; I predict that if the PPMS trial is positive Fingolimod will be the first drug to be licensed as a neuroprotective therapy in MS. …
21 Mar 2011
(1) Fingolimod is approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS. …